Relevância clínica e frequência de padrões citoplasmático e pontilhado fino denso observados em FAN-HEp-2

Pazini, Andréia Martini; Fleck, Juliana; Santos, Rosane Souza dos; Beck, Sandra Trevisan

doi:10.1590/s0482-50042010000600006

Cited by 13 publications

(2 citation statements)

References 19 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). We found 1.7% of anti-DFS70 positive sera, in line with some previous studies conducted on routine ANA screening population 6,10,13,16,19,21,34 . In fact, Mahler et al .…”

Section: Discussionsupporting

confidence: 92%

Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort

Carbone

Pafundi

Tramontano³

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Anti-Dense Fine Speckled 70 (DFS70) antibodies are a common finding in clinical laboratory referrals. High prevalence of DFS70 autoantibodies in healthy population and usual negative association with Antinuclear Antibody (ANA)-associated autoimmune rheumatic diseases (AARD) were reported. The aim of this study was to evaluate the prevalence of DFS70 autoantibodies and their association with other autoantibodies in the context of a routine ANA referral cohort. Consecutive sera submitted for ANA screening were analyzed for anti-DFS70 antibodies by indirect immunofluorescence (IIF) (n = 3175, 1030 men and 2145 women) then confirmed by immunoblotting. Anti-DFS70 positive samples were also assayed for a large spectrum of other circulating autoantibodies. The prevalence of anti-DFS70 antibodies was 1.7% in the whole population and 4.6% in the ANA-positive samples. Comparison between DFS70 IIF and immunoblotting showed an excellent correlation between the two methods. The prevalence of anti-DFS70 positive was significantly higher in females (2.1%, 45/2145) than in males (1.0%, 10/1030). Of note, no concomitant autoantibodies were found in the DFS70-positive male group compared with DFS70-positive females group that showed other serum autoantibodies in the 51% of cases. Anti-DFS70 reactivity in male population may represent an useful biomarker predicting the absence of other autoantibodies. On the contrary, the serological profile of DFS70-positive females required further investigations in order to define the presence of concomitant disease-marker autoantibodies.

show abstract

“…1). We found 1.7% of anti-DFS70 positive sera, in line with some previous studies conducted on routine ANA screening population 6,10,13,16,19,21,34 . In fact, Mahler et al .…”

Section: Discussionsupporting

confidence: 92%

Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort

Carbone

Pafundi

Tramontano³

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The prevalence of anti-DFS70 antibodies has been reported to vary, but consistent findings are that they are present in healthy ANA positive individuals even when ANA reach moderate or high titers, and that they are rarely found in patients with CTD [17, 33, 34]. Fitch-Rogalsky et al [35] investigated 643 patients with a positive ANA and found that 15% were anti-DFS70 antibody positive and 91% of these did not have an autoimmune disease.…”

Section: Discussionmentioning

confidence: 99%

Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia

et al. 2019

View full text Add to dashboard Cite

Background: Anti-DFS70 antibodies, corresponding to the dense fine speckled antinuclear antibody (ANA) pattern in HEp-2 substrates, have been observed in chronic inflammatory conditions, cancer and in healthy individuals but in only a small percentage of patients with connective tissue diseases (CTD). Objectives: The study was aimed to investigate the possible role of Anti-DFS70 antibodies to distinguish CTD associated interstitial lung disease (CTD-ILD) from idiopathic interstitial pneumonia (IIP) and to explore potential correlations between anti-DFS70 antibodies and clinical parameters. Methods: Serum samples were collected from 49 healthy controls (HC), 35 scleroderma-ILD (SSc-ILD) patients as negative controls for anti-DFS70 antibody, and 260 patients with the initial diagnosis IIP including 100 nonspecific interstitial pneumonia (NSIP) and 160 idiopathic pulmonary fibrosis (IPF) patients. ANA pattern was identified by indirect immunofluorescence on HEp-2 cells and anti-DFS70 antibodies were measured in serum by ELISA. Results: Serum anti-DFS70 antibodies were less frequently seen in ILD and SSc-ILD patients compared to HCs. Thirty-seven patients (34 initial idiopathic NSIP and 3 initial IPF patients) developed CTD during 24 months of follow-up, most of them combined with ANA positivity and anti-DFS70 antibody negativity. Anti-DFS70 antibody positivity was not significantly different between CTD-ILD and idiopathic ILD. Conclusions: The frequency of serum anti-DFS70 antibody is markedly decreased in patients with ILDs. Anti-DFS70 antibodies may be useful to predict CTD development in ILD patients.

show abstract

Antinukleäre Antikörper ohne Kollagenose

Mierau

2016

Z Rheumatol

View full text Add to dashboard Cite

Testing for antinuclear antibodies (ANA) by the indirect immunofluorescence test (IFT) is regarded as a fundamental serological screening method for diagnosing connective tissue diseases (CTD). In the case of a negative result exclusion of certain CTDs is indicated, especially systemic lupus erythematosus, and a positive ANA result is the starting point for further tests aimed at finding disease-specific autoantibodies. The recently discovered antibodies against lens epithelium-derived growth factor (LEDGF/DSF70) deviate from the normal interpretation pattern in ANA diagnostics. These antibodies give rise to a characteristic dense fine speckled (DSF) immunofluorescence pattern in IFT and target the ubiquitously expressed nuclear stress protector protein LEDGFp75. They can be detected, sometimes in high titers, not only in patients with diverse disorders of the skin or eyes and with neoplasms but also in persons with relatively mild or unspecific complaints and even in apparently healthy individuals; however, they are less frequent in CTD. These anti-LEDGF antibodies can be found in all age groups with a tendency to a higher prevalence in younger people and the frequency does not increase in advanced age. The vast majority of anti-LEDGF carriers are female. The CTDs with isolated anti-LEDGF antibodies, i. e. unaccompanied by autoantibodies typical for the respective CTD, are extremely rare. Detection of ANA exclusively with a DSF immunofluorescence pattern and confirmed by a specific anti-LEDGF binding assay, does not therefore indicate the presence of CTD but is indicative of exclusion of systemic lupus erythematosus, systemic sclerosis and an ANA-associated overlap syndrome, similar to a completely negative ANA result.

show abstract

Relevância clínica e frequência de padrões citoplasmático e pontilhado fino denso observados em FAN-HEp-2

Cited by 13 publications

References 19 publications

Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort

Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort

Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia

Antinukleäre Antikörper ohne Kollagenose

Contact Info

Product

Resources

About